6499 logo

Medeon Biodesign, Inc. Stock Price

TPEX:6499 Community·NT$8.8b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

6499 Share Price Performance

NT$90.70
50.50 (125.62%)
NT$90.70
50.50 (125.62%)
Price NT$90.70

6499 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

High growth potential with excellent balance sheet.

1 Risk
2 Rewards

Medeon Biodesign, Inc. Key Details

NT$419.4m

Revenue

NT$360.6m

Cost of Revenue

NT$58.8m

Gross Profit

NT$726.9m

Other Expenses

-NT$668.1m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-6.89
14.03%
-159.28%
0%
View Full Analysis

About 6499

Founded
2012
Employees
n/a
CEO
Yue-Teh Jang
WebsiteView website
www.medeonbiodesign.com

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.

Recent 6499 News & Updates

Recent updates

No updates